Cannabidiol (Epidyolex®) for the treatment of Tuberous Sclerosis Complex. HTA ID: 21024
Cannabidiol is indicated for use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 09/06/2021 |
| Rapid review completed | 08/07/2021 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cannabidiol (Epidyolex®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |